SlideShare a Scribd company logo
1 of 2
Download to read offline
ULTRA ZX LABS, L.L.C. ISSUES VOLUNTARY NATIONWIDE
RECALL OF ULTRA ZX SINCE IT CONTAINS UNDECLARED
SIBUTRAMINE AND PHENOLPHTHALEIN
Ultra ZX LABS, L.L.C. Issues Voluntary Nationwide Recall of Ultra ZX Since It Contains Undeclared
Sibutramine and Phenolphthalein
Contact:
Consumer:
(305) 896-5611 Wilson Crespo
FOR IMMEDIATE RELEASE — March 10, 2015 — Miami, Florida — UltaZx, Labs, L.L.C. is voluntarily
recalling “UltraZx” weight loss supplements. This product has been found to contain undeclared
Sibutramine and phenolphthalein.
FDA laboratory analysis of confirmed that UltraZx contains sibutramine and phenolphthalein.
Sibutramine is a controlled substance that was removed from the market in October 2010 for safety
reasons. The product poses a threat to consumers because sibutramine is known to substantially
increase blood pressure and/or pulse rate in some patients and may present a significant risk for
patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.
Phenolphthalein is a chemical that is not an active ingredient in any approved drug in the United
States. Studies have indicated that it presents a cancer causing risk. This product may also interact,
in life-threating ways, with other medications a consumer may be taking.
Ultra ZX LABS, L.L.C. has not received any reports of adverse events related to this recall. UltraZx
weight loss supplement is marketed as a dietary supplement used as a weight loss aid and is
packaged in bottles of thirty (30) capsules of 300mg. The affected UltraZx weight loss supplement,
includes all lots/bottles/packages. The products were distributed from September 2014 until
February 2015.
UltraZx Labs, L.L.C. is notifying its distributors and customers by letter and is arranging for return
of all recalled products. Consumers and distributors that have product which is being recalled
should stop using the product and return the product to UltraZx Labs, L.L.C.
Consumers with questions regarding this recall can contact UltraZx Labs, L.L.C. at (305) 896-5611,
Vitamin & Supplements Store
11309 NW 62 Terrace, Miami, FL 33178, United States. Wilson Crespo Monday through Friday from
9:00am – 5:00pm EST. Consumers should contact their physician or healthcare provider if they have
experienced any problems that may be related to taking or using this product.
This recall is being conducted with the knowledge of the Food and Drug Administration (FDA).
Adverse reactions or quality problems experienced with the use of this product may be reported to
the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
• Complete and submit the report Online: http://www.fda.gov/medwatch/report.htm
• Regular Mail or Fax: Download form http://www.fda.gov/MedWatch/getforms.htm or call 1-80-
-332-1088 to request a reporting form, then complete and return to the address on the pre-
addressed form, or submit by fax to 1-800-FDA-0178.
###
RSS Feed for FDA Recalls Information [what’s this?]
Photo: Product Labels
Recalled Product Photos Are Also Available on FDA’s Flickr Photostream.
* We believe that none of the products being recalled were processed or offered through the
national office.
* We strongly encourage you to notify your agencies within one business day from receipt of this
notice.
* ALL cased and uncased inventories, both at the member level and agency level, need to be
checked. This product may have entered member and agency warehouses through salvage, local
donations, TEFAP, local purchases, retail pickups, food drives, or other avenues.
* For additional local details, please contact the Health Department(s) for the area(s) your food bank
serves.

More Related Content

Similar to Ultra ZX Labs Recalls Weight Loss Supplement Due to Undeclared Drugs

Fda med watch
Fda med watchFda med watch
Fda med watchSridhar S
 
Chloroquine phosphate 250 mg tablets pil, taj pharmaceuticals.
Chloroquine phosphate 250 mg tablets pil, taj pharmaceuticals.Chloroquine phosphate 250 mg tablets pil, taj pharmaceuticals.
Chloroquine phosphate 250 mg tablets pil, taj pharmaceuticals.Taj Pharma
 
EPVC newsletter sixty one -february 2015
EPVC newsletter sixty one -february 2015EPVC newsletter sixty one -february 2015
EPVC newsletter sixty one -february 2015amin mohamed
 
Chloroquine phosphate syrup pil, taj pharmaceuticals.
Chloroquine phosphate syrup pil, taj pharmaceuticals.Chloroquine phosphate syrup pil, taj pharmaceuticals.
Chloroquine phosphate syrup pil, taj pharmaceuticals.Taj Pharma
 
Initiation Of Warfarin Pharmacotherapy Final Version
Initiation Of Warfarin Pharmacotherapy Final VersionInitiation Of Warfarin Pharmacotherapy Final Version
Initiation Of Warfarin Pharmacotherapy Final VersionMmorshed217
 
Oxyrecall Pro Recall November 2013 Attorneys 404 451 7781
Oxyrecall Pro  Recall November 2013 Attorneys 404 451 7781Oxyrecall Pro  Recall November 2013 Attorneys 404 451 7781
Oxyrecall Pro Recall November 2013 Attorneys 404 451 7781mzamoralaw
 
Antisense Therapeutics (ASX: ANP) Investor Roadshow Presentation Sept 2015
Antisense Therapeutics (ASX: ANP) Investor Roadshow Presentation Sept 2015Antisense Therapeutics (ASX: ANP) Investor Roadshow Presentation Sept 2015
Antisense Therapeutics (ASX: ANP) Investor Roadshow Presentation Sept 2015Symposium
 
Malaria Cure
Malaria CureMalaria Cure
Malaria Curecriwt
 
Report drug failure and adverse reactions with medications and suspected coun...
Report drug failure and adverse reactions with medications and suspected coun...Report drug failure and adverse reactions with medications and suspected coun...
Report drug failure and adverse reactions with medications and suspected coun...Marilu Escorche
 
Multivitamin capsules smpc taj pharmaceuticals
Multivitamin capsules smpc  taj pharmaceuticalsMultivitamin capsules smpc  taj pharmaceuticals
Multivitamin capsules smpc taj pharmaceuticalsTaj Pharma
 
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015Sathish Vemula
 
Restricteddrugpate
RestricteddrugpateRestricteddrugpate
Restricteddrugpatecqpate
 
Booklet POSTER Drug related problem Community Pharm
Booklet POSTER Drug related problem Community PharmBooklet POSTER Drug related problem Community Pharm
Booklet POSTER Drug related problem Community PharmNusirat Bello
 
GPs’ role in quality use of medicines in Australia
GPs’ role in quality use of medicines in AustraliaGPs’ role in quality use of medicines in Australia
GPs’ role in quality use of medicines in AustraliaTGA Australia
 
TGA presentation: Postmarket Monitoring
TGA presentation: Postmarket MonitoringTGA presentation: Postmarket Monitoring
TGA presentation: Postmarket MonitoringTGA Australia
 
AJP Sept 08_p52-53
AJP Sept 08_p52-53AJP Sept 08_p52-53
AJP Sept 08_p52-53Steven Chong
 

Similar to Ultra ZX Labs Recalls Weight Loss Supplement Due to Undeclared Drugs (20)

PM Procare Diamond - Medicine Listed - TGA, Australia
PM Procare Diamond - Medicine Listed - TGA, AustraliaPM Procare Diamond - Medicine Listed - TGA, Australia
PM Procare Diamond - Medicine Listed - TGA, Australia
 
Fda med watch
Fda med watchFda med watch
Fda med watch
 
Chloroquine phosphate 250 mg tablets pil, taj pharmaceuticals.
Chloroquine phosphate 250 mg tablets pil, taj pharmaceuticals.Chloroquine phosphate 250 mg tablets pil, taj pharmaceuticals.
Chloroquine phosphate 250 mg tablets pil, taj pharmaceuticals.
 
EPVC newsletter sixty one -february 2015
EPVC newsletter sixty one -february 2015EPVC newsletter sixty one -february 2015
EPVC newsletter sixty one -february 2015
 
Chloroquine phosphate syrup pil, taj pharmaceuticals.
Chloroquine phosphate syrup pil, taj pharmaceuticals.Chloroquine phosphate syrup pil, taj pharmaceuticals.
Chloroquine phosphate syrup pil, taj pharmaceuticals.
 
Initiation Of Warfarin Pharmacotherapy Final Version
Initiation Of Warfarin Pharmacotherapy Final VersionInitiation Of Warfarin Pharmacotherapy Final Version
Initiation Of Warfarin Pharmacotherapy Final Version
 
Oxyrecall Pro Recall November 2013 Attorneys 404 451 7781
Oxyrecall Pro  Recall November 2013 Attorneys 404 451 7781Oxyrecall Pro  Recall November 2013 Attorneys 404 451 7781
Oxyrecall Pro Recall November 2013 Attorneys 404 451 7781
 
Antisense Therapeutics (ASX: ANP) Investor Roadshow Presentation Sept 2015
Antisense Therapeutics (ASX: ANP) Investor Roadshow Presentation Sept 2015Antisense Therapeutics (ASX: ANP) Investor Roadshow Presentation Sept 2015
Antisense Therapeutics (ASX: ANP) Investor Roadshow Presentation Sept 2015
 
Malaria Cure
Malaria CureMalaria Cure
Malaria Cure
 
Pl gf
Pl gfPl gf
Pl gf
 
Report drug failure and adverse reactions with medications and suspected coun...
Report drug failure and adverse reactions with medications and suspected coun...Report drug failure and adverse reactions with medications and suspected coun...
Report drug failure and adverse reactions with medications and suspected coun...
 
Multivitamin capsules smpc taj pharmaceuticals
Multivitamin capsules smpc  taj pharmaceuticalsMultivitamin capsules smpc  taj pharmaceuticals
Multivitamin capsules smpc taj pharmaceuticals
 
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
 
Restricteddrugpate
RestricteddrugpateRestricteddrugpate
Restricteddrugpate
 
Booklet POSTER Drug related problem Community Pharm
Booklet POSTER Drug related problem Community PharmBooklet POSTER Drug related problem Community Pharm
Booklet POSTER Drug related problem Community Pharm
 
Drug Safety Alert 6 Acetaminophen
Drug Safety Alert 6 AcetaminophenDrug Safety Alert 6 Acetaminophen
Drug Safety Alert 6 Acetaminophen
 
GPs’ role in quality use of medicines in Australia
GPs’ role in quality use of medicines in AustraliaGPs’ role in quality use of medicines in Australia
GPs’ role in quality use of medicines in Australia
 
TGA presentation: Postmarket Monitoring
TGA presentation: Postmarket MonitoringTGA presentation: Postmarket Monitoring
TGA presentation: Postmarket Monitoring
 
AJP Sept 08_p52-53
AJP Sept 08_p52-53AJP Sept 08_p52-53
AJP Sept 08_p52-53
 
Tamiflu and clinical study reports
Tamiflu and clinical study reportsTamiflu and clinical study reports
Tamiflu and clinical study reports
 

Ultra ZX Labs Recalls Weight Loss Supplement Due to Undeclared Drugs

  • 1. ULTRA ZX LABS, L.L.C. ISSUES VOLUNTARY NATIONWIDE RECALL OF ULTRA ZX SINCE IT CONTAINS UNDECLARED SIBUTRAMINE AND PHENOLPHTHALEIN Ultra ZX LABS, L.L.C. Issues Voluntary Nationwide Recall of Ultra ZX Since It Contains Undeclared Sibutramine and Phenolphthalein Contact: Consumer: (305) 896-5611 Wilson Crespo FOR IMMEDIATE RELEASE — March 10, 2015 — Miami, Florida — UltaZx, Labs, L.L.C. is voluntarily recalling “UltraZx” weight loss supplements. This product has been found to contain undeclared Sibutramine and phenolphthalein. FDA laboratory analysis of confirmed that UltraZx contains sibutramine and phenolphthalein. Sibutramine is a controlled substance that was removed from the market in October 2010 for safety reasons. The product poses a threat to consumers because sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke. Phenolphthalein is a chemical that is not an active ingredient in any approved drug in the United States. Studies have indicated that it presents a cancer causing risk. This product may also interact, in life-threating ways, with other medications a consumer may be taking. Ultra ZX LABS, L.L.C. has not received any reports of adverse events related to this recall. UltraZx weight loss supplement is marketed as a dietary supplement used as a weight loss aid and is packaged in bottles of thirty (30) capsules of 300mg. The affected UltraZx weight loss supplement, includes all lots/bottles/packages. The products were distributed from September 2014 until February 2015. UltraZx Labs, L.L.C. is notifying its distributors and customers by letter and is arranging for return of all recalled products. Consumers and distributors that have product which is being recalled should stop using the product and return the product to UltraZx Labs, L.L.C. Consumers with questions regarding this recall can contact UltraZx Labs, L.L.C. at (305) 896-5611, Vitamin & Supplements Store 11309 NW 62 Terrace, Miami, FL 33178, United States. Wilson Crespo Monday through Friday from 9:00am – 5:00pm EST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product. This recall is being conducted with the knowledge of the Food and Drug Administration (FDA). Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
  • 2. • Complete and submit the report Online: http://www.fda.gov/medwatch/report.htm • Regular Mail or Fax: Download form http://www.fda.gov/MedWatch/getforms.htm or call 1-80- -332-1088 to request a reporting form, then complete and return to the address on the pre- addressed form, or submit by fax to 1-800-FDA-0178. ### RSS Feed for FDA Recalls Information [what’s this?] Photo: Product Labels Recalled Product Photos Are Also Available on FDA’s Flickr Photostream. * We believe that none of the products being recalled were processed or offered through the national office. * We strongly encourage you to notify your agencies within one business day from receipt of this notice. * ALL cased and uncased inventories, both at the member level and agency level, need to be checked. This product may have entered member and agency warehouses through salvage, local donations, TEFAP, local purchases, retail pickups, food drives, or other avenues. * For additional local details, please contact the Health Department(s) for the area(s) your food bank serves.